NEW YORK, July 15, 2026, 17:09 EDT
Pfizer Inc. NYSE:PFE shares rose 2.35% to $24.82 on Wednesday after Sanofi SA NASDAQ:SNY brought a new patent case over the Comirnaty COVID-19 vaccine. The gain suggests investors viewed the complaint as a possible charge against past vaccine earnings, rather than an immediate block on sales.
The historical base is far larger than today’s franchise. Pfizer reported about $95.8 billion in Comirnaty revenue from 2021 through the first quarter of 2026. At Wednesday’s market value of $142.2 billion, an amount equal to 1% of that revenue pool would be roughly $958 million, or 0.7% of Pfizer’s equity value. That is a sensitivity check, not a damages estimate; liability would depend on patent validity, infringement, applicable dates and geography, and what portion of sales a court attributes to the claimed technology.
Pfizer-reported Comirnaty revenue
| Period | Revenue | Change |
|---|---|---|
| 2021 | $36.78 billion | — |
| 2022 | $37.81 billion | +2.8% |
| 2023 | $11.22 billion | -70.3% |
| 2024 | $5.35 billion | -52.3% |
| 2025 | $4.37 billion | -18.4% |
| Q1 2026 | $0.23 billion | -59% vs Q1 2025 |
Translate Bio filed the case on Tuesday in New Jersey federal court. The complaint says Pfizer’s lipid nanoparticles, tiny protective shells that carry mRNA into cells, use patented delivery technology developed by Translate Bio. Sanofi, which bought the biotechnology company for $3.2 billion in 2021, said it was “seeking fair compensation for use of its patented technology” and was not seeking to stop vaccine sales. Pfizer had not immediately responded to a request for comment. Reuters
Current revenue is much smaller. Comirnaty brought in $232 million during the first quarter, down 59%, as lower contractual deliveries overseas and a narrower U.S. vaccination recommendation weighed on demand. The case therefore concerns a large past sales base attached to a product that is now a minor part of quarterly revenue. That split helps explain Wednesday’s share reaction.
Shares of other companies directly exposed to the litigation also rose. Sanofi’s U.S.-listed shares gained about 1.1%, while Moderna Inc. NASDAQ:MRNA, also sued by Sanofi, advanced roughly 1.2%. Pfizer’s vaccine partner BioNTech SE NASDAQ:BNTX added about 1.7%. Same-day prices do not resolve the legal merits, but no immediate sector-wide discount appeared.
Pfizer already faced a crowded set of cases. Its March 29 quarterly filing listed five other claimant groups in Comirnaty patent actions before Sanofi’s complaint, covering litigation in the United States and Europe. Results have split: the U.S. Patent Office held two Moderna patents invalid, while a British appeals court upheld a finding that another patent was valid and infringed. Patent counts alone are a weak proxy for eventual liability.
One public benchmark is Moderna’s March settlement of a separate dispute over lipid-nanoparticle technology. Moderna agreed to pay $950 million upfront and as much as another $1.3 billion, for a maximum of $2.25 billion. Jefferies analyst Andrew Tsai said the agreement “removes the worst-case scenario” of possible double-digit royalty rates and described the payment as small against Moderna’s roughly $48 billion in past vaccine sales. The patents and defenses differ, so the deal is a scale marker, not a precedent for Pfizer. Reuters
Using those reported figures and Pfizer’s March 29 balance sheet, the comparisons below measure scale rather than estimated legal exposure.
Litigation scale checks
| Comparison | Amount | Relative to Pfizer |
|---|---|---|
| Hypothetical 1% of reported 2021–Q1 2026 Comirnaty revenue | $958 million | 0.7% of market value |
| Separate Moderna settlement maximum | $2.25 billion | 1.6% of market value |
| Pfizer cash and short-term investments at March 29 | $13.1 billion | 5.8 times the Moderna benchmark |
Balance-sheet choices still make the figures relevant. Pfizer held $60.6 billion in long-term debt at the end of the first quarter, paid $2.4 billion in dividends during the period and said its current guidance assumes no share repurchases in 2026. A large judgment or settlement could slow debt reduction or leave less room for acquisitions even if vaccine supply continued unchanged.
But Wednesday’s rise may understate a low-probability, high-cost outcome. Sanofi could lose if its patents are found invalid or not infringed, or win damages on only a narrow slice of sales. A broad victory would add another potentially large demand alongside several pending cases. Pfizer’s filing says damages can be enhanced as much as threefold when infringement is found to be willful.
Near-term earnings still depend more on non-COVID medicines. Pfizer said first-quarter revenue excluding Comirnaty and Paxlovid grew 7% operationally, meaning before currency swings, and maintained 2026 revenue guidance of $59.5 billion to $62.5 billion, with adjusted earnings of $2.80 to $3.00 a share. For now, the stock is treating Sanofi’s complaint as a capital-allocation issue, not a sales interruption.
Related articles: NYSE:PFE
